for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalent Inc

CTLT.N

Latest Trade

61.58USD

Change

0.01(+0.02%)

Volume

227,327

Today's Range

61.30

 - 

61.87

52 Week Range

34.98

 - 

61.98

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Catalent Reports Q1 Loss Per Share $0.05

Nov 5 (Reuters) - Catalent Inc <CTLT.N>::CATALENT, INC. REPORTS FIRST QUARTER FISCAL 2020 RESULTS.SEES FY 2020 REVENUE $2.78 BILLION TO $2.88 BILLION.Q1 REVENUE $664.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $636.7 MILLION.Q1 LOSS PER SHARE $0.05.Q1 EARNINGS PER SHARE ESTIMATE $0.24 -- REFINITIV IBES DATA.SEES FY ADJUSTED EBITDA IN RANGE OF $700 MILLION TO $730 MILLION.SEES FY ADJUSTED NET INCOME IN RANGE OF $300 MILLION TO $330 MILLION.FY2020 REVENUE VIEW $2.84 BILLION -- REFINITIV IBES DATA.REAFFIRMING FISCAL YEAR 2020 FINANCIAL GUIDANCE RANGE.

Acura Pharmaceuticals Says Co Engaged Catalent Pharma Solutions To Initiate Manufacturing Scale-Up Of LTX-03 Tablets

Sept 9 (Reuters) - Acura Pharmaceuticals Inc <ACUR.PK>::ACURA PHARMACEUTICALS - ENGAGED CATALENT PHARMA SOLUTIONS TO INITIATE MANUFACTURING SCALE-UP OF LTX-03 TABLETS TO ULTIMATELY BE USED IN CLINICAL TESTING.

Catalent Biologics Announces Agreement To Provide Production For Spinal Muscular Atrophy

July 16 (Reuters) - Catalent Inc <CTLT.N>::CATALENT INC. - CATALENT ANNOUNCES AGREEMENT TO PROVIDE PRODUCTION FOR SPINAL MUSCULAR ATROPHY.CATALENT INC - AVEXIS WILL HAVE DEDICATED MANUFACTURING SPACE AT NEW COMMERCIAL MANUFACTURING CENTER NEAR BALTIMORE-WASHINGTON INTERNATIONAL AIRPORT.CATALENT INC - UNIT TO PROVIDE PROCESS DEVELOPMENT FOR CLINICAL SUPPLY OF ADDITIONAL VIRAL THERAPIES IN AVEXIS PIPELINE.

Catalent Extends Global Commercial Spray Drying Capabilities In Europe

July 9 (Reuters) - Catalent Inc <CTLT.N>::CATALENT EXTENDS GLOBAL COMMERCIAL SPRAY DRYING CAPABILITIES IN EUROPE.CATALENT INC - EXPANDED CAPACITY OF GLOBAL SPRAY DRYING OPERATIONS THROUGH AGREEMENT WITH SANOFI ACTIVE INGREDIENT SOLUTIONS.CATALENT - UNDER AGREEMENT SANOFI TO PROVIDE CO ACCESS TO SPRAY DRYING MANUFACTURING SERVICES FOR CO'S CUSTOMERS AT SANOFI'S HAVERHILL, U.K. FACILITY.

Catalent Announces Pricing Of Private Offering Of Senior Unsecured Notes Due 2027

Catalent Inc <CTLT.N>::CATALENT ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR UNSECURED NOTES DUE 2027.CATALENT INC - CO'S UNIT PRICED A PRIVATE OFFERING OF $500.0 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF 5.00% SENIOR UNSECURED NOTES DUE 2027 AT PAR.

Catalent Announces Launch Of Private Offering Of $500 Million Of Senior Unsecured Notes Due 2027

June 24 (Reuters) - Catalent Inc <CTLT.N>::CATALENT ANNOUNCES LAUNCH OF PRIVATE OFFERING OF $500 MILLION OF SENIOR UNSECURED NOTES DUE 2027.CATALENT - INTENDS TO USE NET PROCEEDS TO REPAY IN FULL OUTSTANDING BORROWINGS UNDER ITS U.S. DOLLAR-DENOMINATED TERM LOANS THAT MATURE IN MAY 2024.

Green Equity Investors VII L.P. Reports A 9% Stake In Catalent Inc As Of May 17 - SEC Filing

May 28 (Reuters) - Catalent Inc <CTLT.N>::GREEN EQUITY INVESTORS VII, L.P. REPORTS A 9% STAKE IN CATALENT INC AS OF MAY 17 - SEC FILING.

Catalent To Buy Gene Therapy Leader Paragon Bioservices For $1.2Bln

April 15 (Reuters) - Catalent Inc <CTLT.N>::CATALENT TO ACQUIRE GENE THERAPY LEADER PARAGON BIOSERVICES, INC. FOR $1.2 BILLION.CATALENT TO ACQUIRE GENE THERAPY LEADER PARAGON BIOSERVICES, INC. FOR $1.2 BILLION.CATALENT INC - PARAGON IS EXPECTED TO ACHIEVE MORE THAN $200 MILLION IN REVENUE IN CALENDAR YEAR 2019.CATALENT INC - CATALENT EXPECTS TRANSACTION TO BE ACCRETIVE TO ITS ADJUSTED NET INCOME PER SHARE IN SECOND FULL FISCAL YEAR AFTER CLOSING.CATALENT INC - CATALENT INTENDS TO FUND TRANSACTION WITH PROCEEDS OF A $650 MILLION INCREMENTAL TERM LOAN.CATALENT INC - DEFINITIVE MERGER AGREEMENT FOR ACQUISITION CONTEMPLATES AN ALL-CASH PURCHASE OF ALL OF PARAGON'S OUTSTANDING EQUITY.CATALENT INC - CATALENT INTENDS TO FUND TRANSACTION WITH ISSUANCE OF $650 MILLION OF A NEW SERIES OF CONVERTIBLE PREFERRED STOCK.CATALENT INC - UPON COMPLETION OF TRANSACTION, PARAGON'S ENTIRE ORGANIZATION WILL REMAIN UNDER LEADERSHIP OF PETE BUZY.CATALENT INC - ACQUISITION CONTEMPLATES AN ALL-CASH PURCHASE OF ALL OF PARAGON'S OUTSTANDING EQUITY FOR $1.2 BILLION ON A CASH-FREE, DEBT-FREE BASIS.CATALENT INC - PETER ZIPPELIUS, A PARTNER AT LGP, WILL JOIN CATALENT'S BOARD OF DIRECTORS.CATALENT - AT JUNE 30, AFTER EXPECTED CLOSING OF ACQUISITION AND RELATED FINANCINGS, PRO FORMA NET LEVERAGE RATIO IS EXPECTED TO BE ABOUT 4.0X.CATALENT INC - CATALENT WILL USE FUNDS REMAINING FROM FINANCINGS TO PAY PORTION OF COSTS OF CAPITAL EXPANSION PROJECTS CURRENTLY UNDERWAY IN MARYLAND.

Contract Drug Manufacturer Catalent To Buy Paragon Bioservices In $1.2 Billion Deal - WSJ

April 14 (Reuters) - :CONTRACT DRUG MANUFACTURER CATALENT TO BUY PARAGON BIOSERVICES IN $1.2 BILLION DEAL - WSJ.

Adial Pharmaceuticals Partners With Catalent To Package And Distribute Adial's AD04 For Its Phase 3 Trial

Feb 20 (Reuters) - Adial Pharmaceuticals Inc <ADIL.O>::ADIAL PHARMACEUTICALS ANNOUNCES PARTNERSHIP WITH CATALENT TO PACKAGE AND DISTRIBUTE ADIAL’S AD04 FOR ITS PHASE 3 TRIAL.ADIAL PHARMACEUTICALS INC - PLANS TO COMMENCE INITIAL PHASE 3 TRIAL OF AD04 IN SCANDINAVIA AND EASTERN EUROPE DURING FIRST HALF OF 2019.ADIAL PHARMACEUTICALS INC - ANNOUNCED A PARTNERSHIP WITH CATALENT PHARMA SOLUTIONS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up